159 related articles for article (PubMed ID: 23205256)
21. Gene silencing of the BDNF/TrkB axis in multiple myeloma blocks bone destruction and tumor burden in vitro and in vivo.
Ai LS; Sun CY; Wang YD; Zhang L; Chu ZB; Qin Y; Gao F; Yan H; Guo T; Chen L; Yang D; Hu Y
Int J Cancer; 2013 Sep; 133(5):1074-84. PubMed ID: 23420490
[TBL] [Abstract][Full Text] [Related]
22. Bone turnover following autologous transplantation in multiple myeloma.
Clark RE; Fraser WD
Leuk Lymphoma; 2002 Mar; 43(3):511-6. PubMed ID: 12002753
[TBL] [Abstract][Full Text] [Related]
23. Angiogenesis-related cytokines, RANKL, and osteoprotegerin in multiple myeloma patients in relation to clinical features and response to treatment.
Sfiridaki K; Pappa CA; Tsirakis G; Kanellou P; Kaparou M; Stratinaki M; Sakellaris G; Kontakis G; Alexandrakis MG
Mediators Inflamm; 2011; 2011():867576. PubMed ID: 21941412
[TBL] [Abstract][Full Text] [Related]
24. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.
Heath DJ; Vanderkerken K; Cheng X; Gallagher O; Prideaux M; Murali R; Croucher PI
Cancer Res; 2007 Jan; 67(1):202-8. PubMed ID: 17210700
[TBL] [Abstract][Full Text] [Related]
25. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index.
Terpos E; Szydlo R; Apperley JF; Hatjiharissi E; Politou M; Meletis J; Viniou N; Yataganas X; Goldman JM; Rahemtulla A
Blood; 2003 Aug; 102(3):1064-9. PubMed ID: 12689925
[TBL] [Abstract][Full Text] [Related]
26. Identification of new targets for therapy of osteolytic bone disease in multiple myeloma.
Hjertner Ø; Standal T; Børset M; Sundan A; Waage A
Curr Drug Targets; 2005 Sep; 6(6):701-11. PubMed ID: 16178802
[TBL] [Abstract][Full Text] [Related]
27. Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma.
Heider U; Langelotz C; Jakob C; Zavrski I; Fleissner C; Eucker J; Possinger K; Hofbauer LC; Sezer O
Clin Cancer Res; 2003 Apr; 9(4):1436-40. PubMed ID: 12684416
[TBL] [Abstract][Full Text] [Related]
28. [The role of RANK/RANKL/osteoprotegerin (OPG) triad in cancer-induced bone diseases: physiopathology and clinical implications].
Clézardin P
Bull Cancer; 2011 Jul; 98(7):837-46. PubMed ID: 21700551
[TBL] [Abstract][Full Text] [Related]
29. Paget's disease of bone and genetic disorders of RANKL/OPG/RANK/NF-kappaB signaling.
Whyte MP
Ann N Y Acad Sci; 2006 Apr; 1068():143-64. PubMed ID: 16831914
[TBL] [Abstract][Full Text] [Related]
30. Role of the RANK/RANKL Pathway in Multiple Myeloma.
Raje NS; Bhatta S; Terpos E
Clin Cancer Res; 2019 Jan; 25(1):12-20. PubMed ID: 30093448
[TBL] [Abstract][Full Text] [Related]
31. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases.
Body JJ; Greipp P; Coleman RE; Facon T; Geurs F; Fermand JP; Harousseau JL; Lipton A; Mariette X; Williams CD; Nakanishi A; Holloway D; Martin SW; Dunstan CR; Bekker PJ
Cancer; 2003 Feb; 97(3 Suppl):887-92. PubMed ID: 12548591
[TBL] [Abstract][Full Text] [Related]
32. Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma.
Oyajobi BO; Mundy GR
Cancer; 2003 Feb; 97(3 Suppl):813-7. PubMed ID: 12548580
[TBL] [Abstract][Full Text] [Related]
33. RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma.
Roux S; Meignin V; Quillard J; Meduri G; Guiochon-Mantel A; Fermand JP; Milgrom E; Mariette X
Br J Haematol; 2002 Apr; 117(1):86-92. PubMed ID: 11918537
[TBL] [Abstract][Full Text] [Related]
34. Pathogenic Mechanisms of Myeloma Bone Disease and Possible Roles for NRF2.
Yen CH; Hsu CM; Hsiao SY; Hsiao HH
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32937821
[TBL] [Abstract][Full Text] [Related]
35. Hepatic osteodystrophy: does the osteoprotegerin/receptor activator of nuclear factor-kB ligand system play a role?
Gaudio A; Lasco A; Morabito N; Atteritano M; Vergara C; Catalano A; Fries W; Trifiletti A; Frisina N
J Endocrinol Invest; 2005 Sep; 28(8):677-82. PubMed ID: 16277162
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of hormone and cytokine-stimulated osteoclastogenesis and bone resorption by interleukin-4 and interleukin-13 is associated with increased osteoprotegerin and decreased RANKL and RANK in a STAT6-dependent pathway.
Palmqvist P; Lundberg P; Persson E; Johansson A; Lundgren I; Lie A; Conaway HH; Lerner UH
J Biol Chem; 2006 Feb; 281(5):2414-29. PubMed ID: 16251181
[TBL] [Abstract][Full Text] [Related]
37. Serum levels of total-RANKL in multiple myeloma.
Jakob C; Goerke A; Terpos E; Sterz J; Heider U; Kühnhardt D; Ziefle S; Kleeberg L; Mieth M; Metzler Iv; Müller C; Sezer O
Clin Lymphoma Myeloma; 2009 Dec; 9(6):430-5. PubMed ID: 19951882
[TBL] [Abstract][Full Text] [Related]
38. Cell-based assay strategy for identification of motif-specific RANK signaling pathway inhibitors.
Chen T; Feng X
Assay Drug Dev Technol; 2006 Aug; 4(4):473-82. PubMed ID: 16945019
[TBL] [Abstract][Full Text] [Related]
39. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.
Croucher PI; Shipman CM; Lippitt J; Perry M; Asosingh K; Hijzen A; Brabbs AC; van Beek EJ; Holen I; Skerry TM; Dunstan CR; Russell GR; Van Camp B; Vanderkerken K
Blood; 2001 Dec; 98(13):3534-40. PubMed ID: 11739154
[TBL] [Abstract][Full Text] [Related]
40. Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing.
Kon T; Cho TJ; Aizawa T; Yamazaki M; Nooh N; Graves D; Gerstenfeld LC; Einhorn TA
J Bone Miner Res; 2001 Jun; 16(6):1004-14. PubMed ID: 11393777
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
